Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02085070 · ClinicalTrials.gov registry record · Phase 2

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

A Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Yale University.

Completed
Registry status
Phase 2
Development phase
65
Enrollment target
1
Study location

NCT02085070: Completed Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by Yale University.

NCT02085070 is a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma that has completed, run by Yale University. The registered enrollment target is 65 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02085070, a Phase 2 study of Non-Small Cell Lung Cancer and Melanoma, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 2
Development phase
65 participants
Enrollment target
1
Study location

Study Summary

The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or non-small cell lung cancer.

Primary Outcome

RECIST criteria v1.1 was modified to account for differences in measuring the response of clinically evaluable brain lesions as opposed to systemic lesions (modified RECIST, or mRECIST). Size was considered the tumor's largest diameter. Measurements from multiple lesions were summed to calculate the sum of the diameters (SD). The SD calculated on a baseline scan performed within 28 days of study drug initiation was used as a reference to determine the objective response of the clinically evaluab

Conditions Studied

Non-Small Cell Lung Cancer Melanoma Brain Metastases

Interventions

  • DRUG MK-3475

Study Locations (1)

Connecticut

  • Smilow Cancer Center at Yale New Haven Hospital - New Haven

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2014-03
Est. Completion 2020-02-27
Phase Phase 2
Yale University

1,492 total trials

What the finished NCT02085070 record still lists

NCT02085070 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower).

The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which MK-3475 is the first listed.

NCT02085070 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT02085070 about?

NCT02085070 is a clinical study titled "MK-3475 in Melanoma and NSCLC Patients With Brain Metastases". The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or non-small cell lung cancer.

What is the current status of trial NCT02085070?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2014-03. Estimated completion is 2020-02-27.

What conditions does trial NCT02085070 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Brain Metastases.

What interventions are being tested in trial NCT02085070?

The interventions under investigation include: MK-3475 (DRUG).

Who is sponsoring clinical trial NCT02085070?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02085070 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02085070's enrollment target sits among peer trials

65 305th of 454 higher than 149 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03366116 · 65 participants · Phase 1

    5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

  • NCT03603730 · 65 participants · NA

    Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis

  • NCT03796559 · 65 participants · NA

    Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

  • NCT03993106 · 65 participants · Phase 2

    A Study of sEphB4-HSA in Kaposi Sarcoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02085070, the US trial registry maintained by the National Library of Medicine. NCT02085070 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.